Skip to main content
Publications
Tam S, Neslund-Dudas C, Barrett AM , Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis . Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Pesantez D, Hoorn ST, Machado I, Garcia-Albeniz X , Rodriguez-Salas N, Heredia-Soto V, Vinal D, Pericay C, Garcia-Carbonero R, Losa F, Alonso V, Vera R, Batlle JF, Gallego J, Salud A, Nogue M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Total neoadjuvant therapy with or without aflibercept in rectal cancer: three-year results of GEMCAD-1402 . J Natl Cancer Inst. 2023 Dec 6;115(12):1497-505. doi: 10.1093/jnci/djad120
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J , Bennett L , Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma . Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Gold BD, Goodwin B, Davis K, Sweeney C , Reynolds M , Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Treatment burden and associated costs in adolescents and adults with eosinophilic esophagitis in the USA . Poster presented at the AMCP Nexus 2021; October 19, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S82.
Garcia-Albeniz X , Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02) . Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Bugner C, Vaccaro J, Schwab P , Cornett D, Drzayich Jankus D, Martinez Vasquez D, Harris J, Sethi M, Cole B. Real-world comparative effectiveness, safety, and health care costs of Sacubitril/ Valsartan versus Angiotensin-II receptor blockers in a Medicare population . Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a):S10.
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J , Hicks K , Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster . Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J , Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma . Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X , Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial . Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509